Tolerability of loteprednol/tobramycin versus dexamethasone/tobramycin in healthy volunteers: results of a 4-week, randomized, double-masked, parallel-group study

References

• Notivol R, Bertin D, Amin D, et al. Comparison of topical tobramycin-dexamethasone with dexamethasone-neomycin-polymyxin and neomycin-polymyxin-gramicidin for control of inflammation after cataract surgery: results of a multicenter, prospective, three-arm, randomized, double-masked, controlled, parallel-group study. Clin Ther 2004;26:1274–851. Notivol R, Bertin D, Amin D, et al. Comparison of topical tobramycin-dexamethasone with dexamethasone-neomycin-polymyxin and neomycin-polymyxin-gramicidin for control of inflammation after cataract surgery: results of a multicenter, prospective, three-arm, randomized, double-masked, controlled, parallel-group study. Clin Ther 2004;26:1274–85
   PubMed Web of Science ®Google Scholar
• Bodor N. Retrometabolic approaches to drug targeting. In: Rapaka RS, ed. Membranes and Barriers: Targeted Drug Delivery. NIDA Research Monograph 154. Rockville, MD: National Institutes of Health, 1995:1–852. Bodor N. Retrometabolic approaches to drug targeting. In: Rapaka RS, ed. Membranes and Barriers: Targeted Drug Delivery. NIDA Research Monograph 154. Rockville, MD: National Institutes of Health, 1995:1–85
   Google Scholar
• Bodor N, Buchwald P. Soft drug design: general principles and recent applications. Med Res Rev 2000;20:58–1013. Bodor N, Buchwald P. Soft drug design: general principles and recent applications. Med Res Rev 2000;20:58–101
   PubMed Web of Science ®Google Scholar
• Bodor N, Buchwald P. Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J 2005;7:E820–334. Bodor N, Buchwald P. Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J 2005;7:E820–33
   PubMed Web of Science ®Google Scholar
• Whitcup SM, Ferris 3rd, FL. New corticosteroids for the treatment of ocular inflammation. Am J Ophthalmol 1999;127:597–95. Whitcup SM, Ferris 3rd, FL. New corticosteroids for the treatment of ocular inflammation. Am J Ophthalmol 1999;127:597–9
   PubMed Web of Science ®Google Scholar
• McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf 2002;25:33–556. McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf 2002;25:33–55
   PubMed Web of Science ®Google Scholar
• Weijtens O, Schoemaker RC, Romijn FP, et al. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. Ophthalmology 2002;109:1887–917. Weijtens O, Schoemaker RC, Romijn FP, et al. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. Ophthalmology 2002;109:1887–91
   PubMed Web of Science ®Google Scholar
• Howes J, Novack GD. Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administration. J Ocul Pharmacol Ther 1998;14:153–88. Howes J, Novack GD. Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administration. J Ocul Pharmacol Ther 1998;14:153–8
   PubMed Web of Science ®Google Scholar
• TobraDex Prescribing Information, 2005, Alcon Pharmaceuticals/Laboratories, Inc.: Fort Worth, Texas, USA9. TobraDex Prescribing Information, 2005, Alcon Pharmaceuticals/Laboratories, Inc.: Fort Worth, Texas, USA
   Google Scholar
• Zylet Prescribing Information, 2005, Bausch & Lomb, Inc.: Tampa, Florida, USA10. Zylet Prescribing Information, 2005, Bausch & Lomb, Inc.: Tampa, Florida, USA
   Google Scholar
• Holland EJ, Bartlett JD, Paterno MR, et al. The effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. Cornea 2008;27:50–511. Holland EJ, Bartlett JD, Paterno MR, et al. The effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. Cornea 2008;27:50–5
   PubMed Web of Science ®Google Scholar
• Wang WW, Mehrotra DV, Chan IS, et al. Statistical considerations for noninferiority/equivalence trials in vaccine development. J Biopharm Stat 2006;16:429–4112. Wang WW, Mehrotra DV, Chan IS, et al. Statistical considerations for noninferiority/equivalence trials in vaccine development. J Biopharm Stat 2006;16:429–41
   PubMed Web of Science ®Google Scholar
• Pavesio CE, DeCory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol 2008;92:455–913. Pavesio CE, DeCory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol 2008;92:455–9
   PubMed Web of Science ®Google Scholar
• Guillon M, Maissa C, Pouliquen P, et al. Effect of povidone 2% preservative-free eyedrops on contact lens wearers with computer visual syndrome: pilot study. Eye Contact Lens 2004;30:34–914. Guillon M, Maissa C, Pouliquen P, et al. Effect of povidone 2% preservative-free eyedrops on contact lens wearers with computer visual syndrome: pilot study. Eye Contact Lens 2004;30:34–9
   PubMedGoogle Scholar
• Bartlett JD, Ophthalmic Drug Facts, 19th edn. St. Louis: Wolters Kluwer Health, 200815. Bartlett JD, Ophthalmic Drug Facts, 19th edn. St. Louis: Wolters Kluwer Health, 2008
   Google Scholar
• White EM, Macy JI, Bateman KM, et al. Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. Curr Med Res Opin 2008;24:287–9616. White EM, Macy JI, Bateman KM, et al. Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. Curr Med Res Opin 2008;24:287–96
   PubMed Web of Science ®Google Scholar